CT-P73

CT-P73 is a next-generation therapeutic candidate being developed by Celltrion, a South Korean biopharmaceutical company. It is part of a series of novel drug candidates (including CT-P71 and CT-P72) that Celltrion plans to advance into clinical development, with Investigational New Drug (IND) applications expected to be submitted sequentially starting in 2025. While specific details regarding its active ingredient, biological target, and primary indications remain proprietary, CT-P73 is identified as either an antibody-drug conjugate (ADC) or a multi-antibody (bispecific or multispecific) therapeutic. This candidate represents Celltrion's strategic expansion into the development of original biologics and innovative modalities beyond its core biosimilar business.